RT Journal Article
T1 HLA association with the susceptibility to anti-synthetase syndrome.
A1 Remuzgo-Martinez, Sara
A1 Atienza-Mateo, Belen
A1 Ocejo-Vinyals, J Gonzalo
A1 Pulito-Cueto, Veronica
A1 Prieto-Peña, Diana
A1 Genre, Fernanda
A1 Marquez, Ana
A1 Llorca, Javier
A1 Mora Cuesta, Victor M
A1 Fernandez, David Iturbe
A1 Riesco, Laura
A1 Ortego-Centeno, Norberto
A1 Gomez, Nair Perez
A1 Mera, Antonio
A1 Martinez-Barrio, Julia
A1 Lopez-Longo, Francisco Javier
A1 Lera-Gomez, Leticia
A1 Moriano, Clara
A1 Diez, Elvira
A1 Tomero, Eva
A1 Calvo-Alen, Jaime
A1 Romero-Bueno, Fredeswinda
A1 Sanchez-Pernaute, Olga
A1 Nuño, Laura
A1 Bonilla, Gema
A1 Grafia, Ignacio
A1 Prieto-Gonzalez, Sergio
A1 Narvaez, Javier
A1 Trallero-Araguas, Ernesto
A1 Selva-O'Callaghan, Albert
A1 Gualillo, Oreste
A1 Martin, Javier
A1 Cavagna, Lorenzo
A1 Castañeda, Santos
A1 Cifrian, Jose M
A1 Renzoni, Elisabetta A
A1 Lopez-Mejias, Raquel
A1 Gonzalez-Gay, Miguel A
K1 Anti-Jo-1 antibodies
K1 Anti-synthetase syndrome
K1 HLA
K1 HLA-B*08:01
K1 HLA-DRB1*03:01
K1 HLA-DRB1*07:01
AB To investigate the human leukocyte antigen (HLA) association with anti-synthetase syndrome (ASSD). We conducted the largest immunogenetic HLA-DRB1 and HLA-B study to date in a homogeneous cohort of 168 Caucasian patients with ASSD and 486 ethnically matched healthy controls by sequencing-based-typing. A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01 alleles in patients with ASSD compared to healthy controls was disclosed (26.2% versus 12.2%, P=1.56E-09, odds ratio-OR [95% confidence interval-CI]=2.54 [1.84-3.50] and 21.4% versus 5.5%, P=18.95E-18, OR [95% CI]=4.73 [3.18-7.05]; respectively). Additionally, HLA-DRB1*07:01 allele was significantly decreased in patients with ASSD compared to controls (9.2% versus 17.5%, P=0.0003, OR [95% CI]=0.48 [0.31-0.72]). Moreover, a statistically significant increase of HLA-DRB1*03:01 allele in anti-Jo-1 positive compared to anti-Jo-1 negative patients with ASSD was observed (31.8% versus 15.5%, P=0.001, OR [95% CI]=2.54 [1.39-4.81]). Similar findings were observed when HLA carrier frequencies were assessed. The HLA-DRB1*03:01 association with anti-Jo-1 was unrelated to smoking history. No HLA differences in patients with ASSD stratified according to the presence/absence of the most representative non-anti-Jo-1 anti-synthetase autoantibodies (anti-PL-12 and anti-PL-7), arthritis, myositis or interstitial lung disease were observed. Our results support the association of the HLA complex with the susceptibility to ASSD.
PB Elsevier Masson
YR 2020
FD 2020-11-13
LK http://hdl.handle.net/10668/16769
UL http://hdl.handle.net/10668/16769
LA en
NO Remuzgo-Martínez S, Atienza-Mateo B, Ocejo-Vinyals JG, Pulito-Cueto V, Prieto-Peña D, Genre F, et al. HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine. 2021 May;88(3):105115.
NO This study was partially supported by grants from the Foundation for Research in Rheumatology (FOREUM); SR-M is supported by funds of the RETICS Program [grant number RD16/0012/0009] from the `Instituto de Salud Carlos III´ (ISCIII), co-funded by the European Regional Development Fund (ERDF); BA-M is a recipient of a ‘López Albo’ Post-Residency Programme funded by Servicio Cántabro de Salud; VP-C is supported by a pre-doctoral grant from IDIVAL [grant number PREVAL 18/01]; LL-G is supported by funds of ISCIII, co-funded by ERDF [grant number PI18/00042]; OG is beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10; EAR is partially supported by Versus Arthritis [grant number 20719] and by Scleroderma and Raynaud's UK [grant number BR11]; RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, ‘Investing in your future’) [grant number CP16/00033].
DS RISalud
RD Apr 5, 2025